<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><publisher><publisher-name>American Medical Association</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408103</article-id><article-id pub-id-type="pmc">PMC12102708</article-id>
<article-id pub-id-type="doi">10.1001/jamanetworkopen.2025.12262</article-id><article-id pub-id-type="publisher-id">zoi250411</article-id><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Pediatrics</subject></subj-group></article-categories><title-group><article-title>Relative Age in School and Initiation of Speech Therapy in Children</article-title><alt-title alt-title-type="headline">Relative Age in School and Initiation of Speech Therapy in Children</alt-title><alt-title alt-title-type="running-head">Relative Age in School and Initiation of Speech Therapy in Children</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Billioti de Gage</surname><given-names>Sophie</given-names></name><degrees>PharmD</degrees><degrees>PhD</degrees><xref rid="zoi250411aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Peyre</surname><given-names>Hugo</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="zoi250411aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zoi250411aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chalumeau</surname><given-names>Martin</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="zoi250411aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="zoi250411aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mikaeloff</surname><given-names>Yann</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="zoi250411aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="zoi250411aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zureik</surname><given-names>Mahmoud</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="zoi250411aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250411aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Weill</surname><given-names>Alain</given-names></name><degrees>MD</degrees><xref rid="zoi250411aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="zoi250411aff1"><label>1</label>EPI-PHARE, Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products and French National Health Insurance), Saint-Denis, France</aff><aff id="zoi250411aff2"><label>2</label>Centre de Ressources Autisme Languedoc-Roussillon et Centre d&#x02019;Excellence sur l&#x02019;Autisme et les Troubles Neuro-d&#x000e9;veloppementaux (CeAND), CHU Montpellier, Montpellier, France</aff><aff id="zoi250411aff3"><label>3</label>Laboratoire de Sciences Cognitives et Psycholinguistique, D&#x000e9;partement d&#x02019;&#x000c9;tudes Cognitives, Ecole Normale Sup&#x000e9;rieure, PSL University, EHESS, CNRS, Paris, France</aff><aff id="zoi250411aff4"><label>4</label>Obstetrical, Perinatal and Pediatric and Life Course Epidemiology Research Team, Centre for Research in Epidemiology and Statistics, Universit&#x000e9; Paris Cit&#x000e9;, Inserm, Paris, France</aff><aff id="zoi250411aff5"><label>5</label>Service de p&#x000e9;diatrie g&#x000e9;n&#x000e9;rale et maladies infectieuses, H&#x000f4;pital Necker-Enfants malades, AP-HP, Universit&#x000e9; Paris Cit&#x000e9;, Paris, France</aff><aff id="zoi250411aff6"><label>6</label>Centre de protection de l&#x02019;enfant et de l&#x02019;adolescent, H&#x000f4;pital Paul-Brousse AP-HP, Villejuif, France</aff><aff id="zoi250411aff7"><label>7</label>Centre for Epidemiology and Population Health, Inserm, Paris-Saclay, Villejuif, France</aff><aff id="zoi250411aff8"><label>8</label>Universit&#x000e9; Versailles Saint-Quentin-en-Yvelines, Universit&#x000e9; Paris Saclay, Guyancourt, France</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> March 23, 2025.</p><p content-type="published-online"><bold>Published:</bold> May 23, 2025. doi:<uri content-type="doi">10.1001/jamanetworkopen.2025.12262</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#x000a9; 2025 Billioti de Gage S et al. <italic>JAMA Network Open</italic>.</p><corresp id="zoi250411cor1"><bold>Corresponding Author:</bold> Sophie Billioti de Gage, PharmD, PhD, EPI-PHARE, 143/147 Blvd Anatole France, 93 285 Saint-Denis CEDEX, France (<email xlink:href="sophie.billioti-de-gage@ansm.sante.fr">sophie.billioti-de-gage@ansm.sante.fr</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Billioti de Gage had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic>Concept and design:</italic> Billioti de Gage, Peyre, Mikaeloff, Zureik, Weill.</p><p><italic>Acquisition, analysis, or interpretation of data:</italic> Billioti de Gage, Chalumeau, Mikaeloff, Zureik.</p><p><italic>Drafting of the manuscript:</italic> Billioti de Gage, Mikaeloff.</p><p><italic>Critical review of the manuscript for important intellectual content:</italic> All authors.</p><p><italic>Statistical analysis:</italic> Billioti de Gage, Mikaeloff, Zureik.</p><p><italic>Administrative, technical, or material support:</italic> Mikaeloff, Zureik, Weill.</p><p><italic>Supervision:</italic> Peyre, Chalumeau, Zureik, Weill.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> None reported.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-05-23T10:00"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>8</volume><issue>5</issue><elocation-id>e2512262</elocation-id><history><date date-type="received"><day>20</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>Copyright 2025 Billioti de Gage S et al. <italic>JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2512262.pdf">jamanetwopen-e2512262.pdf</self-uri><self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.12262"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-zoi250411-1"><title>Question</title><p>What is the association between relative age and initiation of speech therapy in children aged 5 to 10 years?</p></sec><sec id="ab-zoi250411-2"><title>Findings</title><p>In this cohort study of 4 188 985 school-aged children, within the same grade, those born in December (the youngest) were 64% more likely to start speech therapy than those born in January (the oldest). The increase in risk was constant for each month of birth from February to December.</p></sec><sec id="ab-zoi250411-3"><title>Meaning</title><p>These findings suggest that age-related relative immaturity may be misdiagnosed as a learning disability or relative maturity may lead to underdiagnosis of this disorder and that professionals in the field should adapt their practices accordingly.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study used French national health system data to evaluate the association of relative age with the initiation of speech therapy among school-aged children in the same the grade.</p></abstract><abstract><sec id="ab-zoi250411-4"><title>Importance</title><p>In most countries, children in the same grade can be up to 12 months apart in age, which represents a considerable relative age difference, particularly in the early years. A relative age effect has been frequently reported in the diagnosis and treatment of attention-deficit/hyperactivity disorder and, more rarely, in the diagnosis of other neurodevelopmental disorders. The relative age effect has never been studied for speech therapy, which is frequently prescribed to treat specific language and learning disorders.</p></sec><sec id="ab-zoi250411-5"><title>Objective</title><p>To quantify the association of relative age with the initiation of speech therapy.</p></sec><sec id="ab-zoi250411-6"><title>Design, Setting, and Participants</title><p>This cohort study used data from the French National Health Data System and included all children born in France between 2010 and 2016 from September of the year of their 5th birthday until July of the year of their 10th birthday or July 31, 2022 (end of study).</p></sec><sec id="ab-zoi250411-7"><title>Exposure</title><p>Children were categorized according to month of birth.</p></sec><sec id="ab-zoi250411-8"><title>Main Outcomes and Measures</title><p>Risk of speech therapy initiation was estimated using Cox models adjusted for other known risk factors.</p></sec><sec id="ab-zoi250411-9"><title>Results</title><p>In total, 4 188 985 children (mean [SD] age, 5.2 [0.3] years; 50.8% girls) were included. Speech therapy was initiated for 692 086 children (incidence rate, 53.1 per 1000 person-years, 54.5% boys) during a mean (SD) follow-up of 3.1 (1.6) years. Among children of the same schooling level, the risk of initiating speech therapy steadily increased according to quarter and month of birth, with adjusted hazard ratios of 1.51 (95% CI, 1.50-1.52) for children born in the last quarter vs the first quarter and 1.64 (95% CI, 1.62-1.66) for children born in December vs those born in January. The relative age effect observed for speech therapy was of the same magnitude as that observed for methylphenidate in attention-deficit/hyperactivity disorder (positive control outcome). No relative age effect was observed for the initiation of desmopressin for nocturnal enuresis (negative control outcome).</p></sec><sec id="ab-zoi250411-10"><title>Conclusions and Relevance</title><p>This cohort study found that among children in the same grade, an age difference of a few months was associated with the frequency of initiation of speech therapy. These findings may be attributable to a mismatch between the expectations of the school system and the relative age and level of maturity of the children or earlier identification of neurodevelopmental disorders in the youngest children in each age group.</p></sec></abstract></article-meta></front><body><sec id="H1-1-ZOI250411"><title>Introduction</title><p>Specific language and learning disorders are among the most prevalent neurodevelopmental disorders,<sup><xref rid="zoi250411r1" ref-type="bibr">1</xref>,<xref rid="zoi250411r2" ref-type="bibr">2</xref></sup> affecting approximately 8%<sup><xref rid="zoi250411r3" ref-type="bibr">3</xref>,<xref rid="zoi250411r4" ref-type="bibr">4</xref></sup> of school-aged children. These disorders can affect 1 or more cognitive functions, including oral language (difficulties in language comprehension and expression, articulation, fluency, and voice quality),<sup><xref rid="zoi250411r5" ref-type="bibr">5</xref></sup> academic learning (reading, written expression, mathematics),<sup><xref rid="zoi250411r6" ref-type="bibr">6</xref></sup> and gestural and/or visuospatial and transversal functions (attention, memory, executive functions),<sup><xref rid="zoi250411r7" ref-type="bibr">7</xref></sup> and account for a substantial proportion of educational difficulties and failed academic performance.<sup><xref rid="zoi250411r6" ref-type="bibr">6</xref>,<xref rid="zoi250411r8" ref-type="bibr">8</xref></sup> In France, speech therapy, mainly delivered in private practice (ie, outside a hospital or school),<sup><xref rid="zoi250411r9" ref-type="bibr">9</xref></sup> is often prescribed to treat these disorders.<sup><xref rid="zoi250411r7" ref-type="bibr">7</xref>,<xref rid="zoi250411r10" ref-type="bibr">10</xref>,<xref rid="zoi250411r11" ref-type="bibr">11</xref></sup> Studies conducted in France estimated that nearly 10% of children and adolescents younger than 19 received speech therapy in 2019<sup><xref rid="zoi250411r10" ref-type="bibr">10</xref></sup> and that the use of speech therapy for children aged 6 years or older was most often initiated by teachers or parents.<sup><xref rid="zoi250411r7" ref-type="bibr">7</xref>,<xref rid="zoi250411r9" ref-type="bibr">9</xref></sup> Several pre-, peri-, and postnatal factors have been associated with the likelihood of prescribing speech therapy, including male sex, prematurity, and socioeconomic factors.<sup><xref rid="zoi250411r12" ref-type="bibr">12</xref>,<xref rid="zoi250411r13" ref-type="bibr">13</xref></sup></p><p>The relative age effect is the tendency, within age cohorts, of individuals born earlier (ie, older) to perform better. It has been observed in several contexts, notably in top-level sports and academic achievement.<sup><xref rid="zoi250411r14" ref-type="bibr">14</xref>,<xref rid="zoi250411r15" ref-type="bibr">15</xref></sup> Indeed, children in the same grade can be up to 12 months apart in age, representing a substantial relative difference in physical development and cognitive maturity, particularly in the early years. Several international studies have shown that younger children are more likely to be diagnosed or treated for attention-deficit/hyperactivity disorder (ADHD) than older children in the same grade.<sup><xref rid="zoi250411r16" ref-type="bibr">16</xref></sup> Fewer studies have shown the same association with the diagnoses of other neurodevelopmental disorders,<sup><xref rid="zoi250411r17" ref-type="bibr">17</xref></sup> such as autism,<sup><xref rid="zoi250411r18" ref-type="bibr">18</xref>,<xref rid="zoi250411r19" ref-type="bibr">19</xref></sup> intellectual development,<sup><xref rid="zoi250411r19" ref-type="bibr">19</xref>,<xref rid="zoi250411r20" ref-type="bibr">20</xref></sup> developmental motor coordination,<sup><xref rid="zoi250411r21" ref-type="bibr">21</xref></sup> and learning disorders.<sup><xref rid="zoi250411r22" ref-type="bibr">22</xref></sup> The relative age effect has never been studied for speech therapy prescriptions, which may be associated with neurologic maturation and may be influenced by this effect.</p><p>We aimed to quantify the relative age effect on speech therapy initiation among children aged 5 to 10 years in France and to identify potential modulating factors. The magnitude of the effect was compared with that assessed for a positive control outcome (ie, initiation of methylphenidate for ADHD). A negative control outcome (ie, initiation of desmopressin for nocturnal enuresis) was also studied to test the influence of school environment.</p></sec><sec id="H1-2-ZOI250411"><title>Methods</title><sec id="H2-1-ZOI250411"><title>Design and Setting</title><p>This cohort study was conducted using the French National Mother-Child (known as EPI-MERES) register,<sup><xref rid="zoi250411r23" ref-type="bibr">23</xref></sup> which was developed from the French National Health Data System on the basis of algorithms published in previous studies.<sup><xref rid="zoi250411r24" ref-type="bibr">24</xref>,<xref rid="zoi250411r25" ref-type="bibr">25</xref>,<xref rid="zoi250411r26" ref-type="bibr">26</xref></sup> This study was granted permanent regulatory access to EPI-PHARE. No specific authorization or need for informed consent from the French data protection authority was required. The study followed to the Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) reporting guideline.<sup><xref rid="zoi250411r27" ref-type="bibr">27</xref></sup></p><p>The EPI-MERES register includes all pregnancies managed in France since January 2010. For pregnancies resulting in delivery, the mother&#x02019;s and child&#x02019;s information is linked using a unique identifier. The French National Health Data System contains sociodemographic and medical data on all outpatient services reimbursed by national health insurance since 2006, including prescribed drugs and expenditures for long-term diseases and medical and paramedical visits. It also includes diagnoses linked to hospital admissions and procedures performed during hospital stays.<sup><xref rid="zoi250411r28" ref-type="bibr">28</xref>,<xref rid="zoi250411r29" ref-type="bibr">29</xref></sup></p></sec><sec id="H2-2-ZOI250411"><title>Study Population and Follow-Up</title><p>Children born between 2010 and 2016 were included on September 1 of the year of their 5th birthday from 2015 to 2021. Children with congenital malformations or chromosomal abnormalities (eg, Down syndrome); mental, behavioral, or developmental disorders (eg, stress-related disorders, intellectual disability, speech and language disorders, autism spectrum disorders); nervous system disorders (eg, epilepsy); or psychotropic drug prescriptions (ie, anxiolytics, hypnotics, antidepressants, psychostimulants, mood regulators) before study entry were excluded (eTable 1 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>). Children who had received speech therapy before inclusion were also excluded. Children were followed up from inclusion date until the first of the following events: speech therapy initiation, loss to follow-up, death, July 31 of the year of their 10th birthday, or the end of the study period (July 31, 2022) (eFigure 1 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p></sec><sec id="H2-3-ZOI250411"><title>Relative Age</title><p>Date of birth (defined either by quarter or month) was considered as a discrete variable used to estimate age differences within a given grade. In France, children start school the year they turn 3 years, and the school year runs from September to early July. The birth deadline for entering the school year is December 31 (eTable 2 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>). Thus, children born in January are generally the oldest and those born in December are the youngest in their class. In France, repeating a school year has been practiced only exceptionally for children younger than 10 years since 2015, and grade skipping is rare. Furthermore, there is no provision in France for delaying school entry for children born at the end of the year (ie, generally the youngest), meaning that age differences within the same class can be approximated by the month of birth.</p></sec><sec id="H2-4-ZOI250411"><title>Outcomes and Covariates</title><p>The main outcome was speech therapy initiation defined as the first reimbursement since inclusion. Sociodemographic data included sex and at childbirth, the mother&#x02019;s affiliation with solidarity-based complementary health insurance (free access to health care for people with a low income), disadvantage index of the municipality of residence (quintiles, the first corresponding to the most advantaged level),<sup><xref rid="zoi250411r30" ref-type="bibr">30</xref></sup> size of urban area by number of inhabitants, and region of residence. Pregnancy and delivery characteristics were gestational age; birth weight adjusted for age and sex <italic>z</italic> score<sup><xref rid="zoi250411r31" ref-type="bibr">31</xref></sup>; birth rank among siblings (assessed using information on hospital stays at birth that have been available since 2006); and in utero exposure to tobacco (indicator), alcohol (indicator), psychotropic drugs, and valproic acid. The calendar year of inclusion was also considered.</p></sec><sec id="H2-5-ZOI250411"><title>Statistical Analysis</title><sec id="H3-1-ZOI250411"><title>Descriptive Analyses</title><p>Incidence rates of speech therapy use were calculated (1) overall and (2) according to birth month and inclusion year for the 3 cohorts of children with a maximum observation period (ie, children included between 2015 and 2017 followed at most until July 31 of the year of their 10th birthday). The characteristics of the children initiating speech therapy are described in the Results.</p></sec><sec id="H3-2-ZOI250411"><title>Main Analyses</title><p>Survival analyses using Cox models were performed to estimate the association between date of birth and speech therapy initiation. The explanatory variable of interest was either the quarter or month of birth. The reference values considered for the quarter and month of birth were (1) the first quarter and the month of January to measure the widest amplitude of a potential relative age effect or (2) the second quarter and the month of June to approximate the median maturity within an age group. The models were adjusted for the aforementioned covariates.</p></sec><sec id="H3-3-ZOI250411"><title>Subgroup Analyses</title><p>Subgroup analyses were conducted to assess potential modulating factors of the relative age effect on speech therapy initiation according to sex, affiliation with solidarity-based complementary health insurance, disadvantage index of the municipality of residence, birth rank among siblings, and prematurity at birth. The birth date considered was the half-year, with the first half of the year as the reference.</p></sec><sec id="H3-4-ZOI250411"><title>Sensitivity Analyses</title><p>Several sensitivity analyses were conducted. First, we assessed whether the relative age effect was influenced by the school grade by varying the follow-up time, interrupting it successively on July 31 of the year in which the child turned (1) 6 years (end of nursery school), (2) 7 years (end of first elementary class), (3) 8 years (end of second elementary class), and (4) 9 years (end of third elementary class), with all children being followed up until July 31 of the year of their 10th birthday (end of fourth elementary class) in the main analysis (eTable 2 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>). Second, analyses were stratified according to the calendar year of inclusion to assess the period effect, as the use of speech therapy may have changed over time. Third, we assessed whether the relative age effect differed between children who received therapy or not after an initial assessment by the speech therapist. Indeed, the initial assessment should lead to a reduction in a potential relative age effect by considering the child&#x02019;s actual age.</p></sec><sec id="H3-5-ZOI250411"><title>Analyses With Positive and Negative Control Outcomes</title><p>Descriptive and main analyses were replicated on a positive control outcome (ie, initiation of methylphenidate for ADHD [Anatomical Therapeutic Chemical code N06BA04]) to validate our results and compare the magnitude of potential associations between date of birth and speech therapy initiation. The relative age effect was also assessed for desmopressin initiation (mainly indicated for nocturnal enuresis, the diagnosis or management of which does not appear to be predominantly influenced by the school environment [Anatomical Therapeutic Chemical code H01BA02]), which was considered as a negative control outcome to test the influence of the school environment on the main results.</p><p>The data were analyzed using SAS Enterprise Guide, version 8.3 (SAS Institute Inc). A 95% confidence interval around the hazard ratios that did not include 1 defined statistical significance.</p></sec></sec></sec><sec id="H1-3-ZOI250411"><title>Results</title><sec id="H2-6-ZOI250411"><title>Population and Outcomes</title><p>In total, 4 188 985 children (mean [SD] age, 5.2 [0.3] years; 49.2% boys and 50.8% girls) were included (<xref rid="zoi250411f1" ref-type="fig">Figure 1</xref>). A first speech therapy session was initiated for 692 086 children (incidence rate, 53.1 per 1000 person-years, 54.5% boys and 45.5% girls) during a mean (SD) follow-up of 3.1 (1.6) years. The characteristics of speech therapy initiators are described in the <xref rid="zoi250411t1" ref-type="table">Table</xref>. The mean (SD) age at initiation was 6.9 (1.3) years. Compared with children without recourse to speech therapy during follow-up, those with a first recourse were more likely to be boys (54.5% vs 48.1%); to be exposed in utero to tobacco (8.4% vs 7.0%), alcohol (0.6% vs 0.5%), or psychotropic drugs (4.7% vs 3.7%); to be born prematurely (6.5% vs 5.6%); to be born with a low weight for gestational age (12.0% vs 11.0%); to ranked as the second sibling (35.9% vs 34.3%); to live in a more privileged municipality (41.2% vs 38.2% for the first 2 quintiles of the disadvantage index); or to live in an urban area of fewer than 10 000 inhabitants (35.9% vs 32.3%). There were no marked differences between children with a first speech therapy session and those without in terms of affiliation to the solidarity-based complementary health insurance or in utero exposure to valproic acid. Compared with children who did not receive speech therapy, children receiving it were more often born in the last quarter of the year (29.9% vs 24.1%); more likely to live in the Auvergne-Rh&#x000f4;ne-Alpes (13.7% vs 11.6%), Hauts de France (10.6% vs 8.6%), or Occitanie (10.2% vs 8.0%) regions; and less likely to live in the Ile-de-France (including Paris) (13.6% vs 21.4%) or French overseas (2.3% vs 4.1%) regions. For each of the 3 cohorts of children with a maximal observation period, there was a relatively regular increase in the incidence of speech therapy use according to the month of birth from January to December and a systematic sharp decrease in incidence for children born at the beginning of a year vs those born at the end of the previous year (December 2010 to January 2011, from 68.3 to 41.3 per 1000 person-years; December 2011 to January 2012, from 65.8 to 38.7 per 1000 person-years) (<xref rid="zoi250411f2" ref-type="fig">Figure 2</xref>).</p><fig position="float" id="zoi250411f1" fig-type="figure"><label>Figure 1. </label><caption><title>Study Flow Diagram</title><p><sup>a</sup>Including intellectual disability (n&#x02009;=&#x02009;8705); pervasive developmental disorders (n&#x02009;=&#x02009;22 420); other disorders of psychological development (n&#x02009;=&#x02009;10 712); hyperkinetic disorders (n&#x02009;=&#x02009;768); other behavioral and emotional disorders with onset usually occurring in childhood and adolescence (5667); neurotic, stress-related, or mood disorders (n&#x02009;=&#x02009;1249); and schizophrenic, schizotypal, and delusional disorders (n&#x02009;=&#x02009;80).</p><p><sup>b</sup>Including epilepsy (n&#x02009;=&#x02009;16 614) and narcolepsy (n&#x02009;=&#x02009;10).</p><p><sup>c</sup>Including anxiolytics, hypnotics, and sedatives (n&#x02009;=&#x02009;10 699); antipsychotics (n&#x02009;=&#x02009;938); antidepressants or mood regulators (n&#x02009;=&#x02009;317); and methylphenidate (n&#x02009;=&#x02009;232).</p><p><sup>d</sup>Including Down syndrome (n&#x02009;=&#x02009;3240).</p></caption><graphic xlink:href="jamanetwopen-e2512262-g001" position="float"/></fig><table-wrap position="float" id="zoi250411t1"><label>Table. </label><caption><title>Characteristics of Children Initiating Speech Therapy Between the Years of Their 5th and 10th Birthdays</title></caption><table frame="hsides" rules="groups"><col width="45.84%" span="1"/><col width="27.07%" span="1"/><col width="27.09%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Children, No. (%)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Treated with speech therapy (n&#x02009;=&#x02009;692&#x02009;086)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Not treated with speech therapy (n&#x02009;=&#x02009;3&#x02009;496&#x02009;899)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">314&#x02009;813 (45.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02009;813&#x02009;865 (51.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">377&#x02009;273 (54.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1 683&#x02009;034 (48.1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Gestational age, wk</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonmissing</td><td valign="top" align="left" rowspan="1" colspan="1">692&#x02009;073 (100.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02009;496&#x02009;819 (100.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 22-27 (Extremely preterm)</td><td valign="top" align="left" rowspan="1" colspan="1">1374 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">4171 (0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 28-31 (Very preterm)</td><td valign="top" align="left" rowspan="1" colspan="1">4227 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">15 956 (0.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 32-36 (Moderate to late preterm)</td><td valign="top" align="left" rowspan="1" colspan="1">39&#x02009;232 (5.7)</td><td valign="top" align="left" rowspan="1" colspan="1">174&#x02009;661 (5.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 37-40 (Full term)</td><td valign="top" align="left" rowspan="1" colspan="1">523&#x02009;871 (75.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x02009;667&#x02009;410 (76.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#x0003e;40 (Term exceeded or post term)</td><td valign="top" align="left" rowspan="1" colspan="1">123&#x02009;369 (17.8)</td><td valign="top" align="left" rowspan="1" colspan="1">634&#x02009;621 (18.1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Weight for gestational age, percentile<xref rid="zoi250411t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonmissing</td><td valign="top" align="left" rowspan="1" colspan="1">663&#x02009;215 (95.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02009;380&#x02009;500 (96.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#x0003c;3rd (Severe low weight)</td><td valign="top" align="left" rowspan="1" colspan="1">29&#x02009;870 (4.3)</td><td valign="top" align="left" rowspan="1" colspan="1">129&#x02009;868 (3.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#x0003c;10th (Small for gestational age)</td><td valign="top" align="left" rowspan="1" colspan="1">53&#x02009;315 (7.7)</td><td valign="top" align="left" rowspan="1" colspan="1">255&#x02009;559 (7.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 10-90th (Normal weight)</td><td valign="top" align="left" rowspan="1" colspan="1">506&#x02009;201 (73.1)</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x02009;615&#x02009;275 (74.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#x0003e;90th (Macrosomia)</td><td valign="top" align="left" rowspan="1" colspan="1">43&#x02009;926 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">226&#x02009;888 (6.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#x0003e;97th (Severe macrosomia)</td><td valign="top" align="left" rowspan="1" colspan="1">29&#x02009;903 (4.3)</td><td valign="top" align="left" rowspan="1" colspan="1">152&#x02009;910 (4.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">In utero exposure vs nonexposure</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Tobacco</td><td valign="top" align="left" rowspan="1" colspan="1">58&#x02009;177 (8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">244&#x02009;901 (7.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Alcohol</td><td valign="top" align="left" rowspan="1" colspan="1">4483 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#x02009;828 (0.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Psychotropic drugs</td><td valign="top" align="left" rowspan="1" colspan="1">32&#x02009;403 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">129&#x02009;496 (3.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproic acid</td><td valign="top" align="left" rowspan="1" colspan="1">761 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">2761 (0.1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Birth rank among siblings<xref rid="zoi250411t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonmissing</td><td valign="top" align="left" rowspan="1" colspan="1">691&#x02009;840 (100.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02009;495&#x02009;886 (100.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td><td valign="top" align="left" rowspan="1" colspan="1">401&#x02009;343 (58.0)</td><td valign="top" align="left" rowspan="1" colspan="1">2&#x02009;042&#x02009;807 (58.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2</td><td valign="top" align="left" rowspan="1" colspan="1">248&#x02009;523 (35.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02009;198&#x02009;037 (34.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#x02265;3</td><td valign="top" align="left" rowspan="1" colspan="1">41&#x02009;974 (6.1)</td><td valign="top" align="left" rowspan="1" colspan="1">255&#x02009;042 (7.3)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Solidarity-based complementary health insurance</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonmissing</td><td valign="top" align="left" rowspan="1" colspan="1">691&#x02009;011 (99.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02009;491&#x02009;012 (99.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No</td><td valign="top" align="left" rowspan="1" colspan="1">621&#x02009;649 (89.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02009;119&#x02009;832 (89.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Yes</td><td valign="top" align="left" rowspan="1" colspan="1">69&#x02009;362 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">371&#x02009;180 (10.6)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Disadvantage index, quintile<xref rid="zoi250411t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonmissing</td><td valign="top" align="left" rowspan="1" colspan="1">663&#x02009;787 (95.9)</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02009;292&#x02009;826 (94.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1 (Most advantaged)</td><td valign="top" align="left" rowspan="1" colspan="1">138&#x02009;525 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">670&#x02009;561 (19.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2</td><td valign="top" align="left" rowspan="1" colspan="1">146&#x02009;602 (21.2)</td><td valign="top" align="left" rowspan="1" colspan="1">665&#x02009;070 (19.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3</td><td valign="top" align="left" rowspan="1" colspan="1">136&#x02009;533 (19.7)</td><td valign="top" align="left" rowspan="1" colspan="1">646&#x02009;466 (18.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4</td><td valign="top" align="left" rowspan="1" colspan="1">126&#x02009;418 (18.3)</td><td valign="top" align="left" rowspan="1" colspan="1">646&#x02009;876 (18.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 5 (Least advantaged)</td><td valign="top" align="left" rowspan="1" colspan="1">115&#x02009;709 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">663&#x02009;853 (19.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Size of urban area of residence, No. of inhabitants</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonmissing</td><td valign="top" align="left" rowspan="1" colspan="1">677&#x02009;389 (97.9)</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02009;421&#x02009;104 (97.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#x0003c;2000</td><td valign="top" align="left" rowspan="1" colspan="1">151&#x02009;960 (22.0)</td><td valign="top" align="left" rowspan="1" colspan="1">699&#x02009;963 (20.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2000-9999</td><td valign="top" align="left" rowspan="1" colspan="1">95&#x02009;998 (13.9)</td><td valign="top" align="left" rowspan="1" colspan="1">431&#x02009;280 (12.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 10&#x02009;000-49&#x02009;999</td><td valign="top" align="left" rowspan="1" colspan="1">70&#x02009;233 (10.1)</td><td valign="top" align="left" rowspan="1" colspan="1">379&#x02009;604 (10.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 50&#x02009;000-199&#x02009;999</td><td valign="top" align="left" rowspan="1" colspan="1">81&#x02009;526 (11.8)</td><td valign="top" align="left" rowspan="1" colspan="1">450&#x02009;263 (12.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#x02265;200&#x02009;000</td><td valign="top" align="left" rowspan="1" colspan="1">277&#x02009;672 (40.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02009;459&#x02009;994 (41.8)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">French region of residence</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonmissing</td><td valign="top" align="left" rowspan="1" colspan="1">692&#x02009;084 (100.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3&#x02009;496&#x02009;865 (100.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Auvergne-Rh&#x000f4;ne-Alpes</td><td valign="top" align="left" rowspan="1" colspan="1">94&#x02009;967 (13.7)</td><td valign="top" align="left" rowspan="1" colspan="1">406&#x02009;718 (11.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Bourgogne-Franche-Comt&#x000e9;</td><td valign="top" align="left" rowspan="1" colspan="1">24&#x02009;935 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">134&#x02009;983 (3.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Bretagne</td><td valign="top" align="left" rowspan="1" colspan="1">40&#x02009;694 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">161&#x02009;749 (4.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Centre-Val de Loire</td><td valign="top" align="left" rowspan="1" colspan="1">24&#x02009;071 (3.5)</td><td valign="top" align="left" rowspan="1" colspan="1">139&#x02009;518 (4.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Corse</td><td valign="top" align="left" rowspan="1" colspan="1">2878 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">11&#x02009;479 (0.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Grand Est</td><td valign="top" align="left" rowspan="1" colspan="1">58&#x02009;333 (8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">244&#x02009;227 (7.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hauts-de-France</td><td valign="top" align="left" rowspan="1" colspan="1">73&#x02009;432 (10.6)</td><td valign="top" align="left" rowspan="1" colspan="1">300&#x02009;235 (8.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Ile-de-France</td><td valign="top" align="left" rowspan="1" colspan="1">93&#x02009;794 (13.6)</td><td valign="top" align="left" rowspan="1" colspan="1">749&#x02009;306 (21.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Normandie</td><td valign="top" align="left" rowspan="1" colspan="1">31&#x02009;135 (4.5)</td><td valign="top" align="left" rowspan="1" colspan="1">176&#x02009;557 (5.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nouvelle-Aquitaine</td><td valign="top" align="left" rowspan="1" colspan="1">56&#x02009;786 (8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">289&#x02009;542 (8.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Occitanie</td><td valign="top" align="left" rowspan="1" colspan="1">70&#x02009;724 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">279&#x02009;352 (8.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pays de la Loire</td><td valign="top" align="left" rowspan="1" colspan="1">43&#x02009;959 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">206&#x02009;764 (5.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Provence-Alpes-C&#x000f4;te d&#x02019;Azur</td><td valign="top" align="left" rowspan="1" colspan="1">60&#x02009;224 (8.7)</td><td valign="top" align="left" rowspan="1" colspan="1">253&#x02009;535 (7.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> French overseas region</td><td valign="top" align="left" rowspan="1" colspan="1">16&#x02009;152 (2.3)</td><td valign="top" align="left" rowspan="1" colspan="1">142&#x02009;900 (4.1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Year of 5th birthday<xref rid="zoi250411t1n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2015</td><td valign="top" align="left" rowspan="1" colspan="1">134&#x02009;324 (19.4)</td><td valign="top" align="left" rowspan="1" colspan="1">444&#x02009;330 (12.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2016</td><td valign="top" align="left" rowspan="1" colspan="1">133&#x02009;297 (19.3)</td><td valign="top" align="left" rowspan="1" colspan="1">465&#x02009;523 (13.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2017</td><td valign="top" align="left" rowspan="1" colspan="1">131&#x02009;183 (19.0)</td><td valign="top" align="left" rowspan="1" colspan="1">479&#x02009;250 (13.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2018</td><td valign="top" align="left" rowspan="1" colspan="1">112&#x02009;123 (16.2)</td><td valign="top" align="left" rowspan="1" colspan="1">494&#x02009;300 (14.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2019</td><td valign="top" align="left" rowspan="1" colspan="1">88&#x02009;732 (12.8)</td><td valign="top" align="left" rowspan="1" colspan="1">520&#x02009;829 (14.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2020</td><td valign="top" align="left" rowspan="1" colspan="1">63&#x02009;092 (9.1)</td><td valign="top" align="left" rowspan="1" colspan="1">539&#x02009;771 (15.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2021</td><td valign="top" align="left" rowspan="1" colspan="1">29&#x02009;335 (4.2)</td><td valign="top" align="left" rowspan="1" colspan="1">552&#x02009;896 (15.8)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Quarter of birth</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> January-March</td><td valign="top" align="left" rowspan="1" colspan="1">138&#x02009;075 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">877&#x02009;604 (25.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> April-June</td><td valign="top" align="left" rowspan="1" colspan="1">157&#x02009;451 (22.8)</td><td valign="top" align="left" rowspan="1" colspan="1">874&#x02009;124 (25.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> July-September</td><td valign="top" align="left" rowspan="1" colspan="1">189&#x02009;464 (27.4)</td><td valign="top" align="left" rowspan="1" colspan="1">901&#x02009;237 (25.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> October-December</td><td valign="top" align="left" rowspan="1" colspan="1">207&#x02009;096 (29.9)</td><td valign="top" align="left" rowspan="1" colspan="1">843&#x02009;934 (24.1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Month of birth</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> January</td><td valign="top" align="left" rowspan="1" colspan="1">46&#x02009;198 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">305&#x02009;620 (8.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> February</td><td valign="top" align="left" rowspan="1" colspan="1">43&#x02009;491 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">278&#x02009;331 (8.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> March</td><td valign="top" align="left" rowspan="1" colspan="1">48&#x02009;386 (7.0)</td><td valign="top" align="left" rowspan="1" colspan="1">293&#x02009;653 (8.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> April</td><td valign="top" align="left" rowspan="1" colspan="1">48&#x02009;582 (7.0)</td><td valign="top" align="left" rowspan="1" colspan="1">282&#x02009;661 (8.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> May</td><td valign="top" align="left" rowspan="1" colspan="1">53&#x02009;707 (7.8)</td><td valign="top" align="left" rowspan="1" colspan="1">299&#x02009;349 (8.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> June</td><td valign="top" align="left" rowspan="1" colspan="1">55&#x02009;162 (8.0)</td><td valign="top" align="left" rowspan="1" colspan="1">292&#x02009;114 (8.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> July</td><td valign="top" align="left" rowspan="1" colspan="1">61&#x02009;672 (8.9)</td><td valign="top" align="left" rowspan="1" colspan="1">308&#x02009;223 (8.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> August</td><td valign="top" align="left" rowspan="1" colspan="1">63&#x02009;457 (9.2)</td><td valign="top" align="left" rowspan="1" colspan="1">300&#x02009;175 (8.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> September</td><td valign="top" align="left" rowspan="1" colspan="1">64&#x02009;335 (9.3)</td><td valign="top" align="left" rowspan="1" colspan="1">292&#x02009;839 (8.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> October</td><td valign="top" align="left" rowspan="1" colspan="1">68&#x02009;249 (9.9)</td><td valign="top" align="left" rowspan="1" colspan="1">294&#x02009;265 (8.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> November</td><td valign="top" align="left" rowspan="1" colspan="1">67&#x02009;278 (9.7)</td><td valign="top" align="left" rowspan="1" colspan="1">272&#x02009;635 (7.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> December</td><td valign="top" align="left" rowspan="1" colspan="1">71&#x02009;569 (10.3)</td><td valign="top" align="left" rowspan="1" colspan="1">277&#x02009;034 (7.9)</td></tr></tbody></table><table-wrap-foot><fn id="zoi250411t1n1"><label>
<sup>a</sup>
</label><p>Adjusted for gestational age and sex <italic>z</italic> score.</p></fn><fn id="zoi250411t1n2"><label>
<sup>b</sup>
</label><p>Assessed using information on hospital stays at birth since 2006.</p></fn><fn id="zoi250411t1n3"><label>
<sup>c</sup>
</label><p>Disadvantage index of the municipality of residence.</p></fn><fn id="zoi250411t1n4"><label>
<sup>d</sup>
</label><p>Due to the study design, the maximum duration of follow-up was shorter for children included after 2017.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="zoi250411f2" fig-type="figure"><label>Figure 2. </label><caption><title>Incidence of Recourse to Speech Therapy by Birth Month and Year of Study Entry for Children Born Between 2010 and 2012 Who Received the Maximum Follow-Up</title><p>Dashed lines illustrate the sharp decrease in incidence of recourse to speech therapy for children born at the beginning of a year vs those born at the end of the previous year.</p></caption><graphic xlink:href="jamanetwopen-e2512262-g002" position="float"/></fig></sec><sec id="H2-7-ZOI250411"><title>Main Analyses</title><p>After adjustment, we observed a steady increase in the risk of speech therapy initiation according to quarter and month of birth, with adjusted hazard ratios (AHRs) of 1.51 (95% CI, 1.50-1.52) for children born in the last quarter vs those born in the first quarter and 1.64 (95% CI, 1.62-1.66) for children born in December vs those born in January. Compared with children born in the second quarter, the risk of initiating speech therapy increased for children born in the last quarter (AHR, 1.34 [95% CI, 1.33-1.34]) and decreased for children born in the first quarter (AHR, 0.88 [95% CI, 0.88-0.89]). Compared with children born in June, there was a steady increase in the risk of speech therapy initiation for children born after June, with an AHR of 1.33 (95% CI, 1.32-1.35) for children born in December, and a decrease for children born before June, with an AHR of 0.81 (95% CI, 0.80-0.82) for children born in January (<xref rid="zoi250411f3" ref-type="fig">Figure 3</xref>).</p><fig position="float" id="zoi250411f3" fig-type="figure"><label>Figure 3. </label><caption><title>Associations Between the Date of Birth (Quarter or Month) and the Initiation of Speech Therapy Between the Years of the 5th and 10th Birthdays</title><p>Models were adjusted for birth quarter (January-March as reference for adjusted hazard ratio 1 [AHR 1] and April-June as reference for AHR 2) or month (January as reference for AHR 1 and June as reference for AHR 2); sex; gestational age; weight for gestational age; birth rank among siblings; in utero exposure to tobacco, alcohol, psychotropic drugs, or valproic acid; solidarity-based complementary health insurance; disadvantage index; size of urban area of residence; French region of residence; and calendar year of inclusion.</p></caption><graphic xlink:href="jamanetwopen-e2512262-g003" position="float"/></fig><p>The other main factors significantly associated with speech therapy initiation were male sex (AHR, 1.28 [95% CI, 1.28-1.29]); prematurity (for extreme vs no prematurity: AHR, 1.71 [95% CI, 1.62-1.80]); low weight for gestational age (for very low vs normal weight: AHR, 1.18 [95% CI, 1.16-1.19]); birth rank among siblings (second child: AHR, 1.15 [95% CI, 1.14-1.15]; third child or more: 1.19 [95% CI, 1.18-1.20]); in utero exposure to tobacco (AHR, 1.12 [95% CI, 1.11-1.13]), alcohol (AHR, 1.10 [95% CI, 1.07-1.14]), psychotropic drugs (AHR, 1.19 [95% CI, 1.18-1.20]), or valproic acid (AHR, 1.16 [95% CI, 1.08-1.24]); and living in a more advantaged municipality (for the least vs the most advantaged quintile: AHR, 0.71 [95% CI, 0.70-0.72]). There were significant variations in the risk of initiating speech therapy according to region of residence, with a notably lower probability for the Ile-de-France (that includes Paris) region (AHR, 0.56 [95% CI, 0.55-0.57]) (<xref rid="zoi250411f4" ref-type="fig">Figure 4</xref>).</p><fig position="float" id="zoi250411f4" fig-type="figure"><label>Figure 4. </label><caption><title>Association Between Adjustment Factors and the Initiation of Speech Therapy</title><p>Models were adjusted for birth quarter; sex; gestational age; weight for gestational age; birth rank among siblings; in utero exposure to tobacco, alcohol, psychotropic drugs, or valproic acid; solidarity-based complementary health insurance; disadvantage index of municipality of residence; size of urban area of residence; French region of residence; and calendar year of inclusion. AHR indicates adjusted hazard ratio.</p></caption><graphic xlink:href="jamanetwopen-e2512262-g004" position="float"/></fig></sec><sec id="H2-8-ZOI250411"><title>Subgroup and Sensitivity Analyses</title><p>The association of date of birth with speech therapy initiation was broadly similar in all subgroup analyses (eTable 3 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>). A relative age effect was observed regardless of grade, but was more marked between age 5 and 7 years (eTable 4 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>). The relative age effect was similar regardless of the year of inclusion (eTable 5 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>) and was slightly higher for children who received therapy than for those who only underwent a single assessment not followed by therapy (eTable 6 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p></sec><sec id="H2-9-ZOI250411"><title>Analyses With Positive and Negative Control Outcomes</title><p>Methylphenidate was initiated for 38 794 children (incidence rate, 2.3 per 1000 person-years) (eTable 7 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>). As observed for speech therapy, the incidence of methylphenidate prescriptions (1) increased fairly steadily with the month of birth (from January to December) for children in the same school year and (2) decreased sharply (from 30% to 37%) between children born at the end of the year and those born at the beginning of the following school year (eFigure 2 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>). Adjusted Cox models indicated a steady increase according to quarter and month of birth, with an AHR of 1.55 (95% CI, 1.47-1.62) for children born in December vs January (eFigure 3 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>). Desmopressin was initiated for 58 589 children (incidence rate, 3.6 per 1000 person-years) (eTable 7 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>). No relative age effect was found for desmopressin initiation (eTable 8 in <xref rid="note-ZOI250411-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p></sec></sec><sec id="H1-4-ZOI250411"><title>Discussion</title><p>This cohort study performed in a nearly exhaustive population of children aged 5 to 10 years living in France shows that the youngest children within the same school grade may be more likely to be prescribed speech therapy. To our knowledge, no other study has investigated this association to date. However, studies have examined the relative age effect between children in the same age group for learning difficulties or academic achievement. They showed a 30% to 100% higher risk of diagnoses related to learning difficulties<sup><xref rid="zoi250411r20" ref-type="bibr">20</xref>,<xref rid="zoi250411r22" ref-type="bibr">22</xref></sup> or lower scholastic results among younger vs older children,<sup><xref rid="zoi250411r20" ref-type="bibr">20</xref>,<xref rid="zoi250411r22" ref-type="bibr">22</xref>,<xref rid="zoi250411r32" ref-type="bibr">32</xref>,<xref rid="zoi250411r33" ref-type="bibr">33</xref></sup> consistent with our findings for speech therapy initiation, which is mainly indicated for specific language and learning disorders in children aged 5 to 10 years. We observed a relative age effect associated with speech therapy use in all subgroup analyses according to sex, birth rank among siblings, gestational age, and socioeconomic level. The relative age effect observed for initiation of speech therapy was of the same order of magnitude as that found for initiation of methylphenidate to treat ADHD in both our study and other international studies.<sup><xref rid="zoi250411r16" ref-type="bibr">16</xref>,<xref rid="zoi250411r20" ref-type="bibr">20</xref>,<xref rid="zoi250411r34" ref-type="bibr">34</xref>,<xref rid="zoi250411r35" ref-type="bibr">35</xref></sup></p><p>It is unlikely that our findings are associated with a biological mechanism linking the season of birth and incidence of specific language and learning disorders and their management. In our study, the incidence rates of speech therapy use fell sharply between children born in December and those born in January of the following year and attending the next lower grade. Environmental risk factors at birth are unlikely to change abruptly between 2 consecutive months in the winter season. Moreover, previous studies have shown that school entry deadlines, even in different seasons, delimited significant changes in rates of diagnosis or treatment of ADHD.<sup><xref rid="zoi250411r16" ref-type="bibr">16</xref>,<xref rid="zoi250411r20" ref-type="bibr">20</xref>,<xref rid="zoi250411r32" ref-type="bibr">32</xref>,<xref rid="zoi250411r33" ref-type="bibr">33</xref></sup></p><p>We expected an influence of the school environment, particularly in the absence of a relative age effect on desmopressin initiation (negative control outcome) in our study. There is growing evidence that children&#x02019;s relative age, as an indicator of their cognitive and psychoaffective development, may be associated with their performance and behavior at school.<sup><xref rid="zoi250411r22" ref-type="bibr">22</xref>,<xref rid="zoi250411r36" ref-type="bibr">36</xref>,<xref rid="zoi250411r37" ref-type="bibr">37</xref></sup> Two hypotheses may explain our results. First, children born within a few months of the school entry deadline, generally the youngest and least mature in their class, might be subjected to overly high demands, especially in the early school years. These children may be less attentive, more hyperactive, and exhibit weaker language development and poorer academic performance than their older classmates and, consequently, may be more likely to be referred for specialized assessments.<sup><xref rid="zoi250411r38" ref-type="bibr">38</xref></sup> Thus, if tested more frequently, younger children in a class might receive more diagnoses of neurodevelopmental disorders, such as learning disabilities or ADHD, and care.<sup><xref rid="zoi250411r20" ref-type="bibr">20</xref>,<xref rid="zoi250411r22" ref-type="bibr">22</xref></sup> A lack of a relative age effect or an attenuated effect was reported for the diagnosis or treatment of ADHD in countries or districts where school entry is commonly delayed depending on the child&#x02019;s maturity (ie, Denmark,<sup><xref rid="zoi250411r39" ref-type="bibr">39</xref>,<xref rid="zoi250411r40" ref-type="bibr">40</xref></sup> Israel,<sup><xref rid="zoi250411r41" ref-type="bibr">41</xref></sup> Scotland,<sup><xref rid="zoi250411r42" ref-type="bibr">42</xref></sup> and New South Wales<sup><xref rid="zoi250411r43" ref-type="bibr">43</xref></sup> vs other Australian states with low rates of delayed school entry<sup><xref rid="zoi250411r44" ref-type="bibr">44</xref></sup>), consistent with this first hypothesis.</p><p>A second, opposite interpretation of the influence of relative age within the class is also possible. Children born earlier and who are, on average, more mature, may find it easier to adapt and, therefore, compensate for clinically relevant symptoms associated with certain neurodevelopmental disorders (ie, learning disabilities, ADHD), which may lead to a reduced likelihood of receiving a diagnosis or treatment.<sup><xref rid="zoi250411r20" ref-type="bibr">20</xref></sup> This possibility is particularly important to consider in the context of limited health care delivery in France for speech therapy in certain parts of the country and child psychiatry throughout the country. Moreover, a recent meta-analysis showed that a diagnosis of ADHD in the youngest children in a class was no more likely to be overturned over time than that of older children in the class, supporting this second hypothesis.<sup><xref rid="zoi250411r45" ref-type="bibr">45</xref></sup></p><p>The risk of initiating speech therapy was always higher among the youngest children, regardless of their grade, and the association predominated for pupils in kindergarten and 1st grade and then diminished. In most other studies that have investigated the relative age effect on the diagnosis or management of ADHD, the influence was more pronounced in grades that included children younger than 10 years<sup><xref rid="zoi250411r16" ref-type="bibr">16</xref></sup> and may be explained by the age difference being greater in relative terms among younger children.</p><p>The lack of change in the relative age effect observed for speech therapy initiation in the analyses according to the calendar year of inclusion of the children may indicate a lack of knowledge in educational and health care communities of this effect in France. The relative age effect was greater among children who had undergone a speech therapy session after the initial checkup than among those who had only received an initial checkup, whereas the checkup should normally have led to a reduction in the relative age effect in favor of considering the children&#x02019;s actual age.</p><sec id="H2-10-ZOI250411"><title>Limitations</title><p>This study had some limitations. First, it was not completely exhaustive due to the exclusion of children lacking a linking identifier to their mother&#x02019;s data (eg, children born abroad or adopted) and the exclusion of same-sex twins for whom certain characteristics cannot be differentiated. However, this limitation concerned only a minority of children. Second, it is possible that some children were wrongly considered within their theoretical grade when they were enrolled in higher grades (eg, in cases of early school entry, particularly for children born in January and February, or in cases of skipping classes), which would mainly contribute to reducing the relative age effect when compared with children enrolled in their theoretical grade. However, such situations are exceptional in France, especially in kindergarten and elementary school. In addition, early transfers of children born at the beginning of the year would not alter the results of analyses evaluating the relative age effect by comparing children born at the end of the year with children born in the second trimester or June.</p></sec></sec><sec id="H1-5-ZOI250411"><title>Conclusions</title><p>In this cohort study in France, the youngest children in a school class were more likely to receive speech therapy compared with the older children. The magnitude of this relative age effect is clinically relevant. Parents, teachers, prescribing physicians, and speech therapists should be aware that age-related relative immaturity may be misdiagnosed as a learning disability or that relative maturity may lead to underdiagnosis of this disorder and adapt their teaching, diagnostic, and therapeutic practices accordingly. Legislators and school administrators might consider introducing greater flexibility for school entry depending on the child&#x02019;s maturity, month of birth, and possible prematurity.</p></sec></body><back><ref-list id="REF-ZOI250411"><title>References</title><ref id="zoi250411r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Franc&#x000e9;s</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Quintero</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Fern&#x000e1;ndez</surname>
<given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Current state of knowledge on the prevalence of neurodevelopmental disorders in childhood according to the DSM-5: a systematic review in accordance with the PRISMA criteria</article-title>. <source>Child Adolesc Psychiatry Ment Health</source>. <year>2022</year>;<volume>16</volume>(<issue>1</issue>):<fpage>27</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13034-022-00462-1</pub-id><pub-id pub-id-type="pmid">35361232</pub-id>
</mixed-citation></ref><ref id="zoi250411r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Zablotsky</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Black</surname>
<given-names>LI</given-names></string-name>, <string-name><surname>Maenner</surname>
<given-names>MJ</given-names></string-name>, <etal/></person-group>. <article-title>Prevalence and trends of developmental disabilities among children in the US: 2009-2017</article-title>. <source>Pediatrics</source>. <year>2019</year>;<volume>144</volume>(<issue>4</issue>):<elocation-id>e20190811</elocation-id>. doi:<pub-id pub-id-type="doi">10.1542/peds.2019-0811</pub-id><pub-id pub-id-type="pmid">31558576</pub-id>
</mixed-citation></ref><ref id="zoi250411r3"><label>3</label><mixed-citation publication-type="book"><person-group><string-name><surname>Boat</surname>
<given-names>TF</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>JT</given-names></string-name></person-group>, eds. <part-title>Prevalence of learning disabilities</part-title>. In: <source>Mental Disorders and Disabilities Among Low-Income Children</source>. <publisher-name>National Academies Press</publisher-name>; <year>2015</year>. Accessed July 1, 2024. <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK332880/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK332880/</ext-link></mixed-citation></ref><ref id="zoi250411r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Prevalence and trends in diagnosed learning disability among US children and adolescents from 1997 to 2021</article-title>. <source>JAMA Pediatr</source>. <year>2023</year>;<volume>177</volume>(<issue>9</issue>):<fpage>969</fpage>-<lpage>972</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapediatrics.2023.2117</pub-id><pub-id pub-id-type="pmid">37428487</pub-id>
</mixed-citation></ref><ref id="zoi250411r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Sharp</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Hillenbrand</surname>
<given-names>K</given-names></string-name></person-group>. <article-title>Speech and language development and disorders in children</article-title>. <source>Pediatr Clin North Am</source>. <year>2008</year>;<volume>55</volume>(<issue>5</issue>):<fpage>1159</fpage>-<lpage>1173, viii</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pcl.2008.07.007</pub-id><pub-id pub-id-type="pmid">18929058</pub-id>
</mixed-citation></ref><ref id="zoi250411r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Chieffo</surname>
<given-names>DPR</given-names></string-name>, <string-name><surname>Arcangeli</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Moriconi</surname>
<given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Specific learning disorders (SLD) and behavior impairment: comorbidity or specific profile?</article-title>
<source>Children (Basel)</source>. <year>2023</year>;<volume>10</volume>(<issue>8</issue>):<fpage>1356</fpage>. doi:<pub-id pub-id-type="doi">10.3390/children10081356</pub-id><pub-id pub-id-type="pmid">37628355</pub-id>
</mixed-citation></ref><ref id="zoi250411r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Willig</surname>
<given-names>TN</given-names></string-name>, <string-name><surname>Henry</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Netter</surname>
<given-names>JC</given-names></string-name>, <etal/></person-group>. <article-title>The organization of diagnosis, care and funding for specific learning and developmental disorders (SLDD): a French regional experimental protocol</article-title>. <source>Front Pediatr</source>. <year>2022</year>;<volume>9</volume>:<elocation-id>652686</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fped.2021.652686</pub-id><pub-id pub-id-type="pmid">35071121</pub-id>
</mixed-citation></ref><ref id="zoi250411r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Delteil</surname>
<given-names>F</given-names></string-name></person-group>. <article-title>Care course in children with specific language and learning disorders</article-title>. <source>Bull Acad Natl Med</source>. <year>2015</year>;<volume>199</volume>(<issue>6</issue>):<fpage>879</fpage>-<lpage>889</lpage>.<pub-id pub-id-type="pmid">29901889</pub-id>
</mixed-citation></ref><ref id="zoi250411r9"><label>9</label><mixed-citation publication-type="webpage">&#x000c9;tude sur les champs d&#x02019;interventions des orthophonistes: les sp&#x000e9;cificit&#x000e9;s et les coop&#x000e9;rations avec d&#x02019;autres professions. Observatoire National de la D&#x000e9;mographie des Professions de Sant&#x000e9;. <year>2011</year>. Accessed July 1, 2024. <ext-link xlink:href="https://sante.gouv.fr/IMG/pdf/Etude_sur_le_metier_d_orthophoniste.pdf" ext-link-type="uri">https://sante.gouv.fr/IMG/pdf/Etude_sur_le_metier_d_orthophoniste.pdf</ext-link></mixed-citation></ref><ref id="zoi250411r10"><label>10</label><mixed-citation publication-type="webpage">Pr&#x000e8;s d&#x02019;un enfant ou adolescent sur dix a eu recours &#x000e0; un orthophoniste lib&#x000e9;ral en 2019, avec des motifs diff&#x000e9;renci&#x000e9;s selon l&#x02019;&#x000e2;ge et le sexe. Direction de la recherche, des &#x000e9;tudes, de l&#x02019;&#x000e9;valuation et des statistiques. Published January 2024. Accessed April 5, 2024. <ext-link xlink:href="https://drees.solidarites-sante.gouv.fr/sites/default/files/2024-01/ER1293.pdf" ext-link-type="uri">https://drees.solidarites-sante.gouv.fr/sites/default/files/2024-01/ER1293.pdf</ext-link></mixed-citation></ref><ref id="zoi250411r11"><label>11</label><mixed-citation publication-type="webpage">Article L4341-1 of the French Public Health Code: the practice of speech and language therapy. French-Business-Law. Published November 7, 2023. Accessed March 26, 2024. <ext-link xlink:href="https://french-business-law.com/french-legislation-art/article-l4341-1-of-the-french-public-health-code/" ext-link-type="uri">https://french-business-law.com/french-legislation-art/article-l4341-1-of-the-french-public-health-code/</ext-link></mixed-citation></ref><ref id="zoi250411r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Morgan</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Hammer</surname>
<given-names>CS</given-names></string-name>, <string-name><surname>Farkas</surname>
<given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Who receives speech/language services by 5 years of age in the United States?</article-title>
<source>Am J Speech Lang Pathol</source>. <year>2016</year>;<volume>25</volume>(<issue>2</issue>):<fpage>183</fpage>-<lpage>199</lpage>. doi:<pub-id pub-id-type="doi">10.1044/2015_AJSLP-14-0201</pub-id><pub-id pub-id-type="pmid">26579989</pub-id>
</mixed-citation></ref><ref id="zoi250411r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Petheram</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Enderby</surname>
<given-names>P</given-names></string-name></person-group>. <article-title>Demographic and epidemiological analysis of patients referred to speech and language therapy at eleven centres 1987-95</article-title>. <source>Int J Lang Commun Disord</source>. <year>2001</year>;<volume>36</volume>(<issue>4</issue>):<fpage>515</fpage>-<lpage>525</lpage>. doi:<pub-id pub-id-type="doi">10.1080/13682820110075015</pub-id><pub-id pub-id-type="pmid">11802501</pub-id>
</mixed-citation></ref><ref id="zoi250411r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Joyner</surname>
<given-names>PW</given-names></string-name>, <string-name><surname>Lewis</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Mallon</surname>
<given-names>WJ</given-names></string-name>, <etal/></person-group>. <article-title>Relative age effect: beyond the youth phenomenon</article-title>. <source>BMJ Open Sport Exerc Med</source>. <year>2020</year>;<volume>6</volume>(<issue>1</issue>):<elocation-id>e000857</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjsem-2020-000857</pub-id><pub-id pub-id-type="pmid">33088587</pub-id>
</mixed-citation></ref><ref id="zoi250411r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Urruticoechea</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Oliveri</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Vernazza</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Gim&#x000e9;nez-Das&#x000ed;</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mart&#x000ed;nez-Arias</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Mart&#x000ed;n-Babarro</surname>
<given-names>J</given-names></string-name></person-group>. <article-title>The relative age effects in educational development: a systematic review</article-title>. <source>Int J Environ Res Public Health</source>. <year>2021</year>;<volume>18</volume>(<issue>17</issue>):<fpage>8966</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijerph18178966</pub-id><pub-id pub-id-type="pmid">34501556</pub-id>
</mixed-citation></ref><ref id="zoi250411r16"><label>16</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Whitely</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Raven</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Timimi</surname>
<given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Attention deficit hyperactivity disorder late birthdate effect common in both high and low prescribing international jurisdictions: a systematic review</article-title>. <source>J Child Psychol Psychiatry</source>. <year>2019</year>;<volume>60</volume>(<issue>4</issue>):<fpage>380</fpage>-<lpage>391</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jcpp.12991</pub-id><pub-id pub-id-type="pmid">30317644</pub-id>
</mixed-citation></ref><ref id="zoi250411r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Bonati</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Cartabia</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zanetti</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Reale</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Didoni</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Costantino</surname>
<given-names>MA</given-names></string-name>; <collab>Lombardy ADHD Group</collab></person-group>. <article-title>Age level vs grade level for the diagnosis of ADHD and neurodevelopmental disorders</article-title>. <source>Eur Child Adolesc Psychiatry</source>. <year>2018</year>;<volume>27</volume>(<issue>9</issue>):<fpage>1171</fpage>-<lpage>1180</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00787-018-1180-6</pub-id><pub-id pub-id-type="pmid">29876753</pub-id>
</mixed-citation></ref><ref id="zoi250411r18"><label>18</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Chen</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>KL</given-names></string-name>, <string-name><surname>Hsu</surname>
<given-names>JW</given-names></string-name>, <etal/></person-group>. <article-title>Effect of relative age on diagnosis of autism spectrum disorder in children: a nationwide study in Taiwan</article-title>. <source>Eur Child Adolesc Psychiatry</source>. <year>2022</year>;<volume>31</volume>(<issue>10</issue>):<fpage>1565</fpage>-<lpage>1571</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00787-021-01791-w</pub-id><pub-id pub-id-type="pmid">33963954</pub-id>
</mixed-citation></ref><ref id="zoi250411r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Hsu</surname>
<given-names>CW</given-names></string-name>, <string-name><surname>Tseng</surname>
<given-names>PT</given-names></string-name>, <string-name><surname>Tu</surname>
<given-names>YK</given-names></string-name>, <etal/></person-group>. <article-title>Month of birth and mental disorders: a population-based study and validation using global meta-analysis</article-title>. <source>Acta Psychiatr Scand</source>. <year>2021</year>;<volume>144</volume>(<issue>2</issue>):<fpage>153</fpage>-<lpage>167</lpage>. doi:<pub-id pub-id-type="doi">10.1111/acps.13313</pub-id><pub-id pub-id-type="pmid">33930177</pub-id>
</mixed-citation></ref><ref id="zoi250411r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Root</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Forbes</surname>
<given-names>HJ</given-names></string-name>, <etal/></person-group>. <article-title>Association of relative age in the school year with diagnosis of intellectual disability, attention-deficit/hyperactivity disorder, and depression</article-title>. <source>JAMA Pediatr</source>. <year>2019</year>;<volume>173</volume>(<issue>11</issue>):<fpage>1068</fpage>-<lpage>1075</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapediatrics.2019.3194</pub-id><pub-id pub-id-type="pmid">31545342</pub-id>
</mixed-citation></ref><ref id="zoi250411r21"><label>21</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Navarro-Pat&#x000f3;n</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Pueyo Villa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mart&#x000ed;n-Ayala</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Mart&#x000ed; Gonz&#x000e1;lez</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mec&#x000ed;as-Calvo</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>Is quarter of birth a risk factor for developmental coordinator disorder in preschool children?</article-title>
<source>Int J Environ Res Public Health</source>. <year>2021</year>;<volume>18</volume>(<issue>11</issue>):<fpage>5514</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijerph18115514</pub-id><pub-id pub-id-type="pmid">34063912</pub-id>
</mixed-citation></ref><ref id="zoi250411r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Arrhenius</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Gyllenberg</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Vuori</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tiiri</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Lempinen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Sourander</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>Relative age and specific learning disorder diagnoses: a Finnish population-based cohort study</article-title>. <source>JCPP Adv</source>. <year>2021</year>;<volume>1</volume>(<issue>1</issue>):<elocation-id>e12001</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/jcv2.12001</pub-id><pub-id pub-id-type="pmid">37431502</pub-id>
</mixed-citation></ref><ref id="zoi250411r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Miranda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Drouin</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Botton</surname>
<given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Registre national de donn&#x000e9;es m&#x000e8;res-enfants &#x000e0; partir du syst&#x000e8;me national des donn&#x000e9;es de sant&#x000e9; pour des &#x000e9;tudes pharmaco-&#x000e9;pid&#x000e9;miologiques</article-title>. <source>Rev Epidemiol Sante Publique</source>. <year>2023</year>;<volume>71</volume>:<elocation-id>101539</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.respe.2023.101539</pub-id></mixed-citation></ref><ref id="zoi250411r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Bloti&#x000e8;re</surname>
<given-names>PO</given-names></string-name>, <string-name><surname>Weill</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dalichampt</surname>
<given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: an application to antiepileptic drug use in 4.9 million pregnant women in France</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2018</year>;<volume>27</volume>(<issue>7</issue>):<fpage>763</fpage>-<lpage>770</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.4556</pub-id><pub-id pub-id-type="pmid">29763992</pub-id>
</mixed-citation></ref><ref id="zoi250411r25"><label>25</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Meyer</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Drouin</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Weill</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Carbonnel</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Dray-Spira</surname>
<given-names>R</given-names></string-name></person-group>. <article-title>Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2020</year>;<volume>52</volume>(<issue>9</issue>):<fpage>1480</fpage>-<lpage>1490</lpage>. doi:<pub-id pub-id-type="doi">10.1111/apt.16074</pub-id><pub-id pub-id-type="pmid">33095502</pub-id>
</mixed-citation></ref><ref id="zoi250411r26"><label>26</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Meyer</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Taine</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Drouin</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Weill</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Carbonnel</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Dray-Spira</surname>
<given-names>R</given-names></string-name></person-group>. <article-title>Serious infections in children born to mothers with inflammatory bowel disease with in utero exposure to thiopurines and anti-tumor necrosis factor</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2022</year>;<volume>20</volume>(<issue>6</issue>):<fpage>1269</fpage>-<lpage>1281.e9</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cgh.2021.07.028</pub-id><pub-id pub-id-type="pmid">34298191</pub-id>
</mixed-citation></ref><ref id="zoi250411r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name><surname>von Elm</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Altman</surname>
<given-names>DG</given-names></string-name>, <string-name><surname>Egger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pocock</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>G&#x000f8;tzsche</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Vandenbroucke</surname>
<given-names>JP</given-names></string-name>; <collab>STROBE Initiative</collab></person-group>. <article-title>Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>BMJ</source>. <year>2007</year>;<volume>335</volume>(<issue>7624</issue>):<fpage>806</fpage>-<lpage>808</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.39335.541782.AD</pub-id><pub-id pub-id-type="pmid">17947786</pub-id>
</mixed-citation></ref><ref id="zoi250411r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Bezin</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Duong</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lassalle</surname>
<given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2017</year>;<volume>26</volume>(<issue>8</issue>):<fpage>954</fpage>-<lpage>962</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.4233</pub-id><pub-id pub-id-type="pmid">28544284</pub-id>
</mixed-citation></ref><ref id="zoi250411r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Tuppin</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Rudant</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Constantinou</surname>
<given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Value of a national administrative database to guide public decisions: from the syst&#x000e8;me national d&#x02019;information interr&#x000e9;gimes de l&#x02019;Assurance Maladie (SNIIRAM) to the syst&#x000e8;me national des donn&#x000e9;es de sant&#x000e9; (SNDS) in France</article-title>. <source>Rev Epidemiol Sante Publique</source>. <year>2017</year>;<volume>65</volume>(<issue>suppl 4</issue>):<fpage>S149</fpage>-<lpage>S167</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.respe.2017.05.004</pub-id><pub-id pub-id-type="pmid">28756037</pub-id>
</mixed-citation></ref><ref id="zoi250411r30"><label>30</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Rey</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Jougla</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Fouillet</surname>
<given-names>A</given-names></string-name>, <string-name><surname>H&#x000e9;mon</surname>
<given-names>D</given-names></string-name></person-group>. <article-title>Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death</article-title>. <source>BMC Public Health</source>. <year>2009</year>;<volume>9</volume>:<fpage>33</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2458-9-33</pub-id><pub-id pub-id-type="pmid">19161613</pub-id>
</mixed-citation></ref><ref id="zoi250411r31"><label>31</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Ego</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Prunet</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lebreton</surname>
<given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Customized and non-customized French intrauterine growth curves. I - Methodology</article-title>. Article in French. <source>J Gynecol Obstet Biol Reprod (Paris)</source>. <year>2016</year>;<volume>45</volume>(<issue>2</issue>):<fpage>155</fpage>-<lpage>164</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jgyn.2015.08.009</pub-id><pub-id pub-id-type="pmid">26422365</pub-id>
</mixed-citation></ref><ref id="zoi250411r32"><label>32</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Aune</surname>
<given-names>TK</given-names></string-name>, <string-name><surname>Ingvaldsen</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Vestheim</surname>
<given-names>OP</given-names></string-name>, <string-name><surname>Bjerkeset</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Dalen</surname>
<given-names>T</given-names></string-name></person-group>. <article-title>Relative age effects and gender differences in the national test of numeracy: a population study of Norwegian children</article-title>. <source>Front Psychol</source>. <year>2018</year>;<volume>9</volume>:<fpage>1091</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpsyg.2018.01091</pub-id><pub-id pub-id-type="pmid">30013499</pub-id>
</mixed-citation></ref><ref id="zoi250411r33"><label>33</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Norbury</surname>
<given-names>CF</given-names></string-name>, <string-name><surname>Gooch</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Baird</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Charman</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Simonoff</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Pickles</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>Younger children experience lower levels of language competence and academic progress in the first year of school: evidence from a population study</article-title>. <source>J Child Psychol Psychiatry</source>. <year>2016</year>;<volume>57</volume>(<issue>1</issue>):<fpage>65</fpage>-<lpage>73</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jcpp.12431</pub-id><pub-id pub-id-type="pmid">26041601</pub-id>
</mixed-citation></ref><ref id="zoi250411r34"><label>34</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Schwandt</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wuppermann</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>The youngest get the pill: ADHD misdiagnosis in Germany, its regional correlates and international comparison</article-title>. <source>Labour Econ</source>. <year>2016</year>;<volume>43</volume>:<fpage>72</fpage>-<lpage>86</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.labeco.2016.05.018</pub-id></mixed-citation></ref><ref id="zoi250411r35"><label>35</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Layton</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Barnett</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Hicks</surname>
<given-names>TR</given-names></string-name>, <string-name><surname>Jena</surname>
<given-names>AB</given-names></string-name></person-group>. <article-title>Attention deficit&#x02013;hyperactivity disorder and month of school enrollment</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>(<issue>22</issue>):<fpage>2122</fpage>-<lpage>2130</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1806828</pub-id><pub-id pub-id-type="pmid">30485780</pub-id>
</mixed-citation></ref><ref id="zoi250411r36"><label>36</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Bedard</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Dhuey</surname>
<given-names>E</given-names></string-name></person-group>. <article-title>The persistence of early childhood maturity: international evidence of long-run age effects</article-title>. <source>Q J Econ</source>. <year>2006</year>;<volume>121</volume>(<issue>4</issue>):<fpage>1437</fpage>-<lpage>1472</lpage>.</mixed-citation></ref><ref id="zoi250411r37"><label>37</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Bell</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Daniels</surname>
<given-names>S</given-names></string-name></person-group>. <article-title>Are summer-born children disadvantaged? the birthdate effect in education</article-title>. <source>Oxf Rev Edu</source>. <year>1990</year>;<volume>16</volume>(<issue>1</issue>):<fpage>66</fpage>-<lpage>80</lpage>.</mixed-citation></ref><ref id="zoi250411r38"><label>38</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Elder</surname>
<given-names>TE</given-names></string-name></person-group>. <article-title>The importance of relative standards in ADHD diagnoses: evidence based on exact birth dates</article-title>. <source>J Health Econ</source>. <year>2010</year>;<volume>29</volume>(<issue>5</issue>):<fpage>641</fpage>-<lpage>656</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jhealeco.2010.06.003</pub-id><pub-id pub-id-type="pmid">20638739</pub-id>
</mixed-citation></ref><ref id="zoi250411r39"><label>39</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Potteg&#x000e5;rd</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hallas</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hern&#x000e1;ndez-D&#x000ed;az</surname></string-name>, <string-name><surname>Zo&#x000eb;ga</surname>
<given-names>H</given-names></string-name></person-group>. <article-title>Children&#x02019;s relative age in class and use of medication for ADHD: a Danish Nationwide Study</article-title>. <source>J Child Psychol Psychiatry</source>. <year>2014</year>;<volume>55</volume>(<issue>11</issue>):<fpage>1244</fpage>-<lpage>1250</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jcpp.12243</pub-id><pub-id pub-id-type="pmid">24813478</pub-id>
</mixed-citation></ref><ref id="zoi250411r40"><label>40</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Dalsgaard</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Humlum</surname>
<given-names>MK</given-names></string-name>, <string-name><surname>Nielsen</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Simonsen</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>Common Danish standards in prescribing medication for children and adolescents with ADHD</article-title>. <source>Eur Child Adolesc Psychiatry</source>. <year>2014</year>;<volume>23</volume>(<issue>9</issue>):<fpage>841</fpage>-<lpage>844</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00787-013-0508-5</pub-id><pub-id pub-id-type="pmid">24374648</pub-id>
</mixed-citation></ref><ref id="zoi250411r41"><label>41</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Hoshen</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Benis</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Keyes</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Zo&#x000eb;ga</surname>
<given-names>H</given-names></string-name></person-group>. <article-title>Stimulant use for ADHD and relative age in class among children in Israel</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2016</year>;<volume>25</volume>(<issue>6</issue>):<fpage>652</fpage>-<lpage>660</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.3962</pub-id><pub-id pub-id-type="pmid">26823045</pub-id>
</mixed-citation></ref><ref id="zoi250411r42"><label>42</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Fleming</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bandyopadhyay</surname>
<given-names>A</given-names></string-name>, <string-name><surname>McLay</surname>
<given-names>JS</given-names></string-name>, <etal/></person-group>. <article-title>Age within schoolyear and attention-deficit hyperactivity disorder in Scotland and Wales</article-title>. <source>BMC Public Health</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>1070</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12889-022-13453-w</pub-id><pub-id pub-id-type="pmid">35637502</pub-id>
</mixed-citation></ref><ref id="zoi250411r43"><label>43</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Hanly</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Edwards</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Goldfeld</surname>
<given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>School starting age and child development in a state-wide, population-level cohort of children in their first year of school in New South Wales, Australia</article-title>. <source>Early Child Res Q</source>. <year>2019</year>;<volume>48</volume>:<fpage>325</fpage>-<lpage>340</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ecresq.2019.01.008</pub-id></mixed-citation></ref><ref id="zoi250411r44"><label>44</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Bruno</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Havard</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hanly</surname>
<given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Children&#x02019;s relative age and medicine treatment for attention-deficit/hyperactivity disorder across Australian jurisdictions with different school enrolment policies</article-title>. <source>J Child Adolesc Psychopharmacol</source>. <year>2022</year>;<volume>32</volume>(<issue>6</issue>):<fpage>349</fpage>-<lpage>357</lpage>. doi:<pub-id pub-id-type="doi">10.1089/cap.2022.0032</pub-id><pub-id pub-id-type="pmid">35917527</pub-id>
</mixed-citation></ref><ref id="zoi250411r45"><label>45</label><mixed-citation publication-type="journal"><person-group><collab>Synergy for the Influence of the Month of Birth in ADHD (SIMBA) Study Group</collab></person-group>. <article-title>Association between relative age at school and persistence of ADHD in prospective studies: an individual participant data meta-analysis</article-title>. <source>Lancet Psychiatry</source>. <year>2023</year>;<volume>10</volume>(<issue>12</issue>):<fpage>922</fpage>-<lpage>933</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2215-0366(23)00272-9</pub-id><pub-id pub-id-type="pmid">37898142</pub-id>
</mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZOI250411-1"><supplementary-material id="note-ZOI250411-1-s" position="float" content-type="local-data"><label>Supplement 1.</label><caption><p><bold>eTable 1.</bold> List of Exclusion Diagnoses and Prescriptions</p><p><bold>eTable 2.</bold> Organization of the School System in France for Children Aged 3 to 10 Years (Primary School)</p><p><bold>eTable 3.</bold> Adjusted Hazard Ratios for the Association Between the Birth Semester and the Initiation of Speech Therapy, Subgroup Analyses</p><p><bold>eTable 4.</bold> Adjusted Hazard Ratios for the Association Between the Quarter of Birth and the Initiation of Speech Therapy, Variation in Length of Follow-Up</p><p><bold>eTable 5.</bold> Adjusted Hazard Ratios for the Association Between the Quarter of Birth and the Initiation of Speech Therapy, by Year of Inclusion in the Study</p><p><bold>eTable 6.</bold> Adjusted Hazard Ratios for the Association Between the Quarter of Birth and the First Checkup for Speech Therapy Followed or Not by Rehabilitation</p><p><bold>eTable 7.</bold> Characteristics of Children Initiating Methylphenidate (Positive Control Outcome) or Desmopressin (Negative Control Outcome) Between the Years of the 5th and 10th Birthdays</p><p><bold>eTable 8.</bold> Adjusted Hazard Ratios for the Association Between the Quarter of Birth and the Initiation of Desmopressin</p><p><bold>eFigure 1.</bold> Follow-Up Scheme</p><p><bold>eFigure 2.</bold> Incidence Rate of Methylphenidate Prescription (Positive Control Outcome) by Birth Month and Calendar Year of Study Entry</p><p><bold>eFigure 3.</bold> Adjusted Hazard Ratios for Associations Between the Date of Birth (Quarter or Month) and the Initiation of Methylphenidate Between the Years of the 5th and 10th Birthdays</p></caption><media xlink:href="jamanetwopen-e2512262-s001.pdf"/></supplementary-material><supplementary-material position="float" content-type="local-data"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xlink:href="jamanetwopen-e2512262-s002.pdf"/></supplementary-material></notes></back></article><!--requester-ID aeutsey-->